Abstract
The article provides an overview of the current literature on the diagnosis and treatment of second-ary (metastatic) damage to the brain substance.
 Over the past years, Russia has seen a high incidence of malignant neoplasms, with a clearly observed upward trend. In 2019, this figure was 376.3 per 100,000 population compared to 369.6 per 100,000 population in 2018 and 293.7 per 100,000 population in 2000. However, thanks to modern methods of diagnosis and treatment, the life span of patients suffering from malignant neo-plasms is significantly increased, and, as a result, the chance of “surviving” before the onset of a metastatic lesion of the brain substance increases. Today, this formidable complication of the tumor process occurs in approximately 8-10% of cancer patients, while in most of them they are symptomatic. In some nosological forms of malig-nant neoplasms (small cell lung cancer, melanoma), the frequency of brain metastasis can reach 80% or more.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
